CLINICAL ROLE -
Carefully Consider Biomarkers, Patient Needs When Initiating Biologics for Asthma
Balancing clinicians’ priorities with the needs of patients and their families is crucial to ensure access and adherence to medications.
Read More
Antimicrobials May Be Associated with Spread of Drug-Resistant C. Difficile Strains
Cephalosporin treatment is a risk factor of Clostridioides difficile infection.
Food Insecurity is a Leading Health-Related Social Need Among Patients With Diabetes
Screening tools are becoming widely used to help clinicians address the needs of patients with diabetes to improve health outcomes.
FDA Gives Final Approval to Sodium Oxybate for Cataplexy or Excessive Daytime Sleepiness in Adults With Narcolepsy
The final approval was based on efficacy and safety data from the phase 3 REST-ON study.
FDA Conditionally Approves First Drug for Nonregenerative Anemia in Cats With Chronic Kidney Disease
Molidustat oral suspension is also the first approval for cats under the FDA’s expanded conditional approval pathway.
Study: Survival Outcome May Not Depend on Choice of Therapy for Patients With Prostate Cancer
Relative risk of cancer-related death differed according to age of diagnosis.
Listen to Patients, Caregivers to Provide Optimal Care in Pediatric Atopic Dermatitis
Pharmacists play key roles in navigating prior authorizations and other limits on utilization, as well as educating and listening to patients and caregivers.
Tirzepatide Promotes Weight Loss in Patients With Obesity or Overweight, Type 2 Diabetes
Nearly 18-times more patients on trizepatide 15 mg achieved a body weight reduction of 15% or more compared to placebo.
Health Awareness Days, Months Serve as Reminders for Pharmacists
Key topics in May include mental illness for pharmacists, pharmacy technicians, and PharmD candidates.
New Therapeutics, Gene Therapies Show Promise in Rett Syndrome
Session at the 2023 Asembia Summit notes that pharmacists play a particularly important role in the large multidisciplinary care team needed for Rett syndrome management.
Health Awareness Days and Months Serve as Reminders for Pharmacists
Issues highlighted in May include mental illness as well as asthma and allergies.
Study: BCG Vaccine Increased Risk of Severe COVID-19 in Certain Populations
The BCG vaccine was more likely to cause symptomatic or severe COVID-19 in patients that had a preexisting condition, such as heart disease, by 6 months.
Pharmacists, Nurses Improve Medication Communication, Patient Experience Through Development of Medication Safety Patient Education Program
Given the increasing value of patient satisfaction in determining the quality of care in the hospital reimbursement model, research is flourishing with a focus on identifying the factors that could positively influence patient satisfaction outcomes.
FDA Approves Risperidone Extended-Release Injectable Suspension for Schizophrenia
The flexible 1- and 2-month dosing intervals of risperidone could help address adherence challenges common with schizophrenia treatments.
Monoclonal Antibody Combination Treatment Not Considered Significantly Effective Against COVID-19
Study shows intramuscular injection may improve treatment success by increasing the speed of drug absorption.
Improved Communication Helps Mental Health Outcomes for Families of Those With SABI
Investigators suggest that a checklist completed by physicians and family members of individuals with severe acute brain injury may improve management needs.
Novavax’s COVID-19 Vaccine Demonstrates Efficacious, Safe Response in Adolescents
Analysis shows that the ratio of neutralizing antibody geometric mean titers in adolescents compared with young adults was 1.5 after vaccination with NVX-CoV2373.
Accelerating Biologics R&D with Unified Software, Data Flows
The willingness of biology labs to evolve has been essential to the incredible rise of biologic drugs.
Pharmacists Are Vital to Transitions of Care
Clinical interventions, follow-ups, medication reconciliation, patient education are key aspects of the programs.
FDA Approves Aripiprazole as First Once-Every-2-Months Long-Acting Injectable for Schizophrenia, Bipolar I Disorder
The formulation in 960 mg and 720 mg prefilled syringes delivers sustained plasma concentrations comparable to those demonstrated in studies with Abilify Maintena.
DEA’s Proposed Rules on Controlled Substances Prescribing via Telemedicine and Their Uncertain Impact on the Pharmacy Community
Proposed rules would permit a telehealth provider to prescribe only up to a 30-day supply of a Schedule III-V non-narcotic controlled substance or buprenorphine through telehealth without the patient first being evaluated in person by a provider.
Pharmacy Times Interactive Case Studies: April 2023
Pharmacists answer questions about blood pressure and antidepressant use during pregnancy.
Report Finds Health-System Workforce Challenges Influence Work of Pharmacists, Technicians
Nearly 84% of hospitals are working to prevent and mitigate burnout, with increased support and programs for individual wellness and resilience practices.
Changing the Game: Pharmacy Students' Perspective on Naloxone OTC Approval
To eliminate the existing stigma in the community, addiction must be recognized as a treatable condition rather than an immoral act.
Pharmacists' Pet Peeves: April 2023
Patient: Is my medication ready?
SARS-CoV-2 Associated With Higher Risk of Diabetes
Risk of incident diabetes was markedly higher among males and in those with more severe COVID-19.
FDA Approves Prevnar 20 Vaccine to Prevent Invasive Pneumococcal Disease in Children 6 Weeks Through 17 Years
Prevnar 20 is a next-generation pneumococcal conjugate vaccine that includes capsular polysaccharide conjugates for the 13 serotypes already included in Prevnar 13.
Trial Shows Iptacopan Lowers Need for Blood Transfusion in Almost All Patients With Paroxysmal Nocturnal Hemoglobinuria
The APPOINT-PNH study showed that twice-daily LNP023 (Iptacopan) helped patients with paroxysmal nocturnal hemoglobinuria control intravascular hemolysis.
Generic Product News: April 2023
PT highlights products from Zydus Lifesciences and Lupin.
FDA Approves First Orally Administered Fecal Microbiota Product for Recurrent C. Diff
Through 8 weeks after treatment, C. difficile recurrence in SER-109-treated participants was lower compared to placebo-treated participants.